AbbVie Inc. (NYSE:ABBV) dropped some good news on Thursday: topline results from its Phase 3 LUNA trial, which tested atogepant as a preventive treatment for menstrual migraines in adults.

Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist. In plain English, it blocks a pathway involved in triggering migraines. The trial gave patients the drug for seven consecutive days, starting three days before menstruation, across three menstrual cycles.

The Numbers That Matter

The drug hit its primary endpoint, showing a greater reduction in perimenstrual migraine days compared to placebo. Patients on atogepant saw an average reduction of 1.20 migraine days, while the placebo group managed just 0.40 days. That's a difference of 0.80 fewer migraine days for those on the active treatment.

That might not sound like a lot, but for someone who loses days every month to debilitating headaches, it's meaningful. And the secondary outcomes back it up: atogepant achieved statistical significance across all eight ranked secondary endpoints. The treatment delivered clinically meaningful improvements in overall headache burden, the need for acute medication, functional disability, and cognitive function.

Commercial Footprint

Atogepant isn't a new kid on the block. It already holds regulatory approval in 60 countries. AbbVie markets it as AQUIPTA in the European Union and as QULIPTA in the U.S., Canada, Israel, and Puerto Rico.

ABBV Price Action: AbbVie shares were up 0.39% at $251.89 at the time of publication on Thursday, according to market data.